Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

StarTric - A novel transcatheter medical device to treat Tricuspid Regurgitation

Objectif

"Tricuspid Regurgitation (TR) poses a significant health challenge, affecting millions worldwide. Current treatment options, primarily open-heart surgery, come with inherent risks and are often unsuitable for frail patients. StarTric has pioneered a transcatheter device tailored to the intricate task of addressing TR. Drawing inspiration from the highly successful open-heart ""clover"" technique, this innovative device offers a minimally invasive alternative for TR repair. The StarTric device will reshape the tricuspid valve into a clover-like configuration, effectively restoring proper valve function. By replicating the efficacy of the clover procedure through transcatheter means, StarTric's solution holds immense promise in transforming the lives of countless patients globally. To bring this breakthrough solution to patients in need, StarTric requires funding support to accelerate development, clinical trials, regulatory approval and commercial efforts."

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-EIC-2024-ACCELERATOR-02

Voir tous les projets financés au titre de cet appel

Coordinateur

STAR TRIC SRL
Contribution nette de l'UE
€ 2 499 999,00
Adresse
Via della Moscova , 3 - 20121
20121 Milano
Italie
PME
Oui
Région
Nord-Ovest Lombardia Milano
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
Aucune donnée